Publication:

Time to Drug-Resistant Tuberculosis Treatment in a Prospective South African Cohort

Loading...
Thumbnail Image

Date

2017

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

SAGE Publications
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

van de Water, Brittney J., Janet Prvu Bettger, Susan Silva, Janice Humphreys, Coleen K. Cunningham, and Jason E. Farley. 2017. “Time to Drug-Resistant Tuberculosis Treatment in a Prospective South African Cohort.” Global Pediatric Health 4 (1): 2333794X17744140. doi:10.1177/2333794X17744140. http://dx.doi.org/10.1177/2333794X17744140.

Abstract

This study examined time to treatment initiation by age among a prospective cohort with drug-resistant tuberculosis (DR-TB). Participants aged 13 years or older nested within a cluster-randomized trial in 2 South African provinces were evaluated. Outcomes were treatment initiation within 5 days of DR-TB diagnosis (National Tuberculosis Program guidelines) and days from diagnosis to treatment. A total of 521 participants met inclusion criteria. Eighty-two patients (16%) met national guidelines; median time to treatment was 11 days (range = 0-180). No patient (age, sex, prior TB history, HIV status) or health system characteristics (geographic urban/rural location, province) were associated with treatment initiation per guidelines except geographic location (t = 3.64, degrees of freedom = 1, P = .0003). One in 6 individuals with DR-TB received treatment per guidelines, and average time to treatment was 11 days. Strategies are needed to decrease treatment delays and meet the recommended guidelines for treatment for patients of all ages.

Description

Research Data

Keywords

tuberculosis, drug-resistance, adolescent medicine, infectious diseases, treatment

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories